OBJECTIVES: To investigate if an insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene associates with HLA-DR alleles previously found to be of prognostic interest in Scandinavian sarcoidosis patients. This may contribute to characteristics associated with these HLA-DR alleles, such as a good (DR17) or poor (DR14 or 15) prognosis. DESIGN, SETTINGS AND SUBJECTS: Polymerase chain reaction (PCR) was used for analysing an I/D polymorphism in the gene coding for ACE in 138 subjects; 65 controls and 73 sarcoidosis patients, and for HLA-DR genotyping 67 patients. Serum ACE level (S-ACE) was measured in all controls and 72 patients. Sixty-one patients were classified as chronic or nonchronic after 2 years follow-up. All patients were recruited and followed at our outpatient clinic. RESULTS: No significant differences in ACE alleles or genotypes were seen between controls and patients or between patients positive and negative for DR17 or DR14/15. The ACE genotype did not differ between nonchronic and chronic patients. The ACE genotype tended to influence the S-ACE in patients, whilst in controls S-ACE significantly differed between the ACE genotypes. CONCLUSION: This study does not support an association between ACE genotype and sarcoidosis or disease outcome. However, because significantly (P < 0.001) more DR17 positive (17 of 19) than DR14/15 positive (seven of 26) patients were classified as nonchronic, these results instead strengthen the prognostic importance of HLA-DR alleles in Scandinavian sarcoidosis patients.
OBJECTIVES: To investigate if an insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene associates with HLA-DR alleles previously found to be of prognostic interest in Scandinavian sarcoidosispatients. This may contribute to characteristics associated with these HLA-DR alleles, such as a good (DR17) or poor (DR14 or 15) prognosis. DESIGN, SETTINGS AND SUBJECTS: Polymerase chain reaction (PCR) was used for analysing an I/D polymorphism in the gene coding for ACE in 138 subjects; 65 controls and 73 sarcoidosispatients, and for HLA-DR genotyping 67 patients. Serum ACE level (S-ACE) was measured in all controls and 72 patients. Sixty-one patients were classified as chronic or nonchronic after 2 years follow-up. All patients were recruited and followed at our outpatient clinic. RESULTS: No significant differences in ACE alleles or genotypes were seen between controls and patients or between patients positive and negative for DR17 or DR14/15. The ACE genotype did not differ between nonchronic and chronic patients. The ACE genotype tended to influence the S-ACE in patients, whilst in controls S-ACE significantly differed between the ACE genotypes. CONCLUSION: This study does not support an association between ACE genotype and sarcoidosis or disease outcome. However, because significantly (P < 0.001) more DR17 positive (17 of 19) than DR14/15 positive (seven of 26) patients were classified as nonchronic, these results instead strengthen the prognostic importance of HLA-DR alleles in Scandinavian sarcoidosispatients.
Authors: Milton D Rossman; Bruce Thompson; Margaret Frederick; Mary Maliarik; Michael C Iannuzzi; Benjamin A Rybicki; Janardan P Pandey; Lee S Newman; Eleni Magira; Bojana Beznik-Cizman; Dimitri Monos Journal: Am J Hum Genet Date: 2003-08-20 Impact factor: 11.025
Authors: Andrea T Borchers; Calvin So; Stanley M Naguwa; Carl L Keen; M Eric Gershwin Journal: Clin Rev Allergy Immunol Date: 2003-12 Impact factor: 8.667
Authors: Esmaeil Mortaz; Hale Abdoli Sereshki; Atefeh Abedini; Arda Kiani; Mehdi Mirsaeidi; Dina Soroush; Johan Garssen; Aliakbar Velayati; Frank A Redegeld; Ian M Adcock Journal: J Inflamm (Lond) Date: 2015-03-19 Impact factor: 4.981
Authors: Anna A Starshinova; Anna M Malkova; Natalia Y Basantsova; Yulia S Zinchenko; Igor V Kudryavtsev; Gennadiy A Ershov; Lidia A Soprun; Vera A Mayevskaya; Leonid P Churilov; Piotr K Yablonskiy Journal: Front Immunol Date: 2020-01-08 Impact factor: 7.561